Avita Medical (ASX:AVH) reported a net loss of $16.2 million, or $0.62 per share, for the third quarter, compared with a net loss of $8.7 million, or $0.34 per share, a year ago, according to a Nov. 8 filing with the Australian bourse.
Total revenue for the three months ended Sept. 30 was $19.5 million, an increase of 44% from $13.6 million in the year-ago period on the strength of Avita's cell harvesting device, Recell GO.
The regenerative medicine company expects commercial revenue for the fourth quarter to rise 58% to 72% year on year to a range of $22.3 million to $24.3 million.
Fiscal 2024 revenue is expected to be within the previous guidance of $68 million to $70 million, reflecting an annual increase of 37% to 41%. The company also reaffirmed guidance of achieving cashflow break-even and GAAP profitability no later than the end of the third quarter of fiscal 2025, the filing stated.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。